In an Israeli trial, severely ill patients treated with Bonus BioGroup's stem-cell based product MesenCure showed significant improvement, reported Globes.
Pharmaceutical industry in the US is set to allocate almost half of its political donations to Democratic candidates in this year’s election to be held next month as the firms look to drive away threat to drug prices if Democrats come to power.